how many glp 1 drugs are there Market Overview: GLP-1 Agonists and the Obesity Market | Blog GLP-1 Market Trends and Global

2026 is the year in which the long-term themes, the true drivers of sustainable success for the burgeoning landscape of obesity treatment, prescription medicines and beyond, become apparent

In 2024, we also saw unprecedented willingness by large numbers of patients to pay out of pocket, even in European markets, as public coverage of AOMs is still limited, at best, and more often non-existent

Blue Cross and Blue Care Network came to this decision after careful consideration of GLP-1 weight loss drugs efficacy, safety and access and skyrocketing costs.

For professionals in pharma, clinical research, and regulatory affairs, this space is evolving fastand full of opportunity

Policy and Global Health Policy advances in 2025 laid critical groundwork for the next phase of obesity care

What is it and what are the pros and cons?